Antiviral nanoagents: More attention and effort needed?
Source abstract
Abstract
The recent COVID-19 outbreak has increasingly engaged researchers in the search for effective antiviral drugs as well as therapeutic treatment options. The shortcomings of existing antiviral agents such as narrow spectrum and low bioavailability, can be overcome through the use of engineered nanomaterials, which, therefore, are considered as a significant next-generation therapeutic option. Thus, the development of novel antiviral nanoagents will certainly help address several future challenges and knowledge gaps.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · SARS-CoV-2 and COVID-19 Research · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Coronavirus disease (COVID-2019) situation reports, WHO, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2. De Clercq · Clin. Microbiol. Rev. · 2016 · 29 · 69510.1128/CMR.00102-15 ↗
3. Li · Nat. Rev. Drug Discov. · 2020 · 19 · 14910.1038/d41573-020-00016-0 ↗
4. World Health Organization: Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, https://www.who.int/csr/sars/country/table2004_04_21/en/.
5. Knobler · 2004
6. World Health Organization · 2018
7. Marshall · Science · 2004 · 303 · 94410.1126/science.303.5660.944 ↗
8. Zhan · J. Med. Chem. · 2016 · 59 · 284910.1021/acs.jmedchem.5b00497 ↗
9. Ianevski · Antiviral Res. · 2018 · 154 · 17410.1016/j.antiviral.2018.04.016 ↗
10. Patel · JAMA · 2020 · 323 · 176910.1001/jama.2020.8946 ↗
11. Ye · ACS Appl. Mater. Interfaces · 2015 · 7 · 2157110.1021/acsami.5b06876 ↗
12. Elechiguerra · J. Nanobiotechnology · 2005 · 3 · 110.1186/1477-3155-3-6 ↗
13. Lara · J. Nanobiotechnology · 2010 · 8 · 110.1186/1477-3155-8-1 ↗
14. Lu · Antivir. Ther. · 2008 · 13 · 25310.1177/135965350801300210 ↗
15. Wan · Cell Death Dis. · 2019 · 10 · 39210.1038/s41419-019-1624-z ↗
16. Sametband · ACS Appl. Mater. Interfaces · 2014 · 6 · 122810.1021/am405040z ↗
17. Zeng · Scientific Reports-UK · 2016 · 6 · 110.1038/s41598-016-0001-8 ↗
18. Cagno · Nat. Mater. · 2018 · 17 · 19510.1038/nmat5053 ↗
19. Lembo · Expert Opin. Drug Deliv. · 2018 · 15 · 9310.1080/17425247.2017.1360863 ↗
20. Choudhary · Int. J. Drug Deliv. · 2013 · 5 · 331
21. Tan · Antiviral Res. · 2017 · 143 · 18610.1016/j.antiviral.2017.04.017 ↗
22. Mastrangelo · ChemMedChem · 2014 · 9 · 93310.1002/cmdc.201300563 ↗
23. Rodríguez-Gascón · Int. J. Nanomedicine · 2014 · 9 · 183310.2147/IJN.S39810 ↗
24. Zholobak · Antiviral Res. · 2016 · 127 · 110.1016/j.antiviral.2015.12.013 ↗
25. Niikura · ACS Nano · 2013 · 7 · 392610.1021/nn3057005 ↗
26. Liu · J. Med. Virol. · 2014 · 86 · 88610.1002/jmv.23768 ↗
27. Draz · Adv. Funct. Mater. · 2016 · 27 · 160413910.1002/adfm.201604139 ↗
28. Wen · Chem. Soc. Rev. · 2016 · 45 · 407410.1039/C5CS00287G ↗
29. Guarner · Am. J. Clin. Pathol. · 2020 · 1
30. Coughlan · Cell Host Microbe · 2018 · 24 · 1810.1016/j.chom.2018.06.016 ↗
31. Zhu · ACS Nano · 2017 · 11 · 263710.1021/acsnano.6b07311 ↗
32. Chapter 7 - Two-dimensional nanoparticles for the delivery of anticancer drugs and cancer therapy
33. Palmieri · Nano Today · 2020 · 3310.1016/j.nantod.2020.100883 ↗
34. Joung · Pharm. Res. · 2012 · 29 · 93210.1007/s11095-011-0633-0 ↗
35. Tahara · Int. J. Pharm. · 2018 · 543 · 31110.1016/j.ijpharm.2018.04.001 ↗
36. Chen · Nanotechnology · 2010 · 21
37. Niikura · ACS Nano · 2013 · 7 · 392610.1021/nn3057005 ↗
38. Quach · Acta Biomater. · 2018 · 78 · 22410.1016/j.actbio.2018.08.011 ↗